Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 14 | 2018 | 2568 | 2.330 |
Why?
|
| Decision Support Techniques | 3 | 2018 | 1998 | 0.780 |
Why?
|
| Health Care Costs | 8 | 2019 | 3238 | 0.700 |
Why?
|
| Cost of Illness | 2 | 2019 | 1935 | 0.650 |
Why?
|
| Multiple Sclerosis | 4 | 2014 | 3222 | 0.620 |
Why?
|
| Venous Thromboembolism | 4 | 2020 | 1866 | 0.560 |
Why?
|
| Venous Thrombosis | 2 | 2018 | 1303 | 0.560 |
Why?
|
| Walking | 2 | 2014 | 1197 | 0.550 |
Why?
|
| Acetanilides | 2 | 2014 | 169 | 0.510 |
Why?
|
| Anticoagulants | 6 | 2020 | 4785 | 0.510 |
Why?
|
| Warfarin | 3 | 2018 | 1477 | 0.500 |
Why?
|
| Quality of Life | 7 | 2019 | 13347 | 0.490 |
Why?
|
| Markov Chains | 3 | 2018 | 965 | 0.490 |
Why?
|
| Sodium Channel Blockers | 1 | 2015 | 172 | 0.480 |
Why?
|
| Risk Assessment | 10 | 2018 | 23972 | 0.460 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 839 | 0.430 |
Why?
|
| Hospital Mortality | 7 | 2019 | 5293 | 0.430 |
Why?
|
| Thrombectomy | 1 | 2018 | 702 | 0.420 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 741 | 0.400 |
Why?
|
| Severity of Illness Index | 7 | 2018 | 15828 | 0.400 |
Why?
|
| Hospitalization | 5 | 2019 | 10704 | 0.370 |
Why?
|
| Coronary Thrombosis | 1 | 2013 | 440 | 0.360 |
Why?
|
| Cost-Benefit Analysis | 8 | 2018 | 5491 | 0.350 |
Why?
|
| Mobility Limitation | 1 | 2014 | 408 | 0.350 |
Why?
|
| Hemorrhage | 3 | 2018 | 3418 | 0.340 |
Why?
|
| Drug Costs | 3 | 2016 | 1183 | 0.340 |
Why?
|
| Standard of Care | 1 | 2014 | 551 | 0.340 |
Why?
|
| Attitude | 1 | 2014 | 772 | 0.310 |
Why?
|
| Health Status Indicators | 1 | 2014 | 969 | 0.310 |
Why?
|
| Automobile Driving | 1 | 2014 | 441 | 0.310 |
Why?
|
| Risk-Taking | 1 | 2014 | 1037 | 0.300 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 1271 | 0.290 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 2057 | 0.280 |
Why?
|
| Ambulatory Care | 1 | 2018 | 2768 | 0.270 |
Why?
|
| Piperazines | 2 | 2014 | 2521 | 0.270 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2291 | 0.270 |
Why?
|
| Neoplasms | 4 | 2020 | 22131 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2017 | 1722 | 0.240 |
Why?
|
| Brain Ischemia | 1 | 2018 | 3028 | 0.230 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 2182 | 0.230 |
Why?
|
| Students | 1 | 2014 | 1733 | 0.220 |
Why?
|
| Data Collection | 1 | 2013 | 3315 | 0.220 |
Why?
|
| Prognosis | 8 | 2019 | 29600 | 0.220 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4308 | 0.210 |
Why?
|
| Veterans | 1 | 2017 | 2649 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2017 | 7960 | 0.200 |
Why?
|
| Models, Economic | 2 | 2017 | 714 | 0.200 |
Why?
|
| Coronary Angiography | 1 | 2013 | 4470 | 0.190 |
Why?
|
| Stents | 1 | 2013 | 3178 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2018 | 10199 | 0.190 |
Why?
|
| Registries | 2 | 2018 | 8207 | 0.190 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 15251 | 0.180 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 4025 | 0.180 |
Why?
|
| Male | 23 | 2019 | 360358 | 0.180 |
Why?
|
| Humans | 39 | 2020 | 760617 | 0.180 |
Why?
|
| Aged | 16 | 2020 | 169042 | 0.180 |
Why?
|
| Female | 25 | 2019 | 392148 | 0.170 |
Why?
|
| Survival Rate | 4 | 2019 | 12719 | 0.170 |
Why?
|
| Middle Aged | 17 | 2019 | 220584 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11736 | 0.170 |
Why?
|
| Health Status | 3 | 2019 | 4075 | 0.150 |
Why?
|
| Melanoma | 1 | 2017 | 5697 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 130 | 0.150 |
Why?
|
| Exercise | 1 | 2014 | 5886 | 0.140 |
Why?
|
| Metformin | 2 | 2015 | 906 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 4416 | 0.140 |
Why?
|
| Equipment Safety | 1 | 2018 | 249 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2019 | 290 | 0.130 |
Why?
|
| United States | 10 | 2020 | 72272 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 857 | 0.130 |
Why?
|
| Stroke | 1 | 2018 | 9712 | 0.130 |
Why?
|
| Retrospective Studies | 10 | 2019 | 80566 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2015 | 9311 | 0.120 |
Why?
|
| Risk Factors | 6 | 2018 | 74115 | 0.120 |
Why?
|
| Enoxaparin | 1 | 2017 | 391 | 0.120 |
Why?
|
| Vital Signs | 1 | 2016 | 144 | 0.120 |
Why?
|
| Comorbidity | 3 | 2018 | 10505 | 0.110 |
Why?
|
| Dacarbazine | 1 | 2017 | 559 | 0.110 |
Why?
|
| Drugs, Generic | 1 | 2019 | 448 | 0.110 |
Why?
|
| Carboplatin | 1 | 2017 | 793 | 0.110 |
Why?
|
| Sulfonylurea Compounds | 1 | 2015 | 219 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 3705 | 0.110 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 3085 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2014 | 381 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 928 | 0.100 |
Why?
|
| Prescription Drugs | 1 | 2019 | 631 | 0.100 |
Why?
|
| Vitamin K | 1 | 2014 | 313 | 0.100 |
Why?
|
| Adult | 11 | 2020 | 220969 | 0.090 |
Why?
|
| New England | 1 | 2014 | 1051 | 0.090 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 58894 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2019 | 1489 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 9172 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2014 | 12334 | 0.080 |
Why?
|
| Placebos | 1 | 2014 | 1667 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6807 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2017 | 1730 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2015 | 1594 | 0.080 |
Why?
|
| Heparin | 1 | 2016 | 1632 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2019 | 64568 | 0.080 |
Why?
|
| Universities | 1 | 2014 | 992 | 0.080 |
Why?
|
| Time Factors | 3 | 2015 | 39913 | 0.080 |
Why?
|
| Accidents, Traffic | 1 | 2014 | 816 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2018 | 2595 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 12142 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 1663 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2014 | 1835 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 11116 | 0.070 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2020 | 344 | 0.070 |
Why?
|
| Length of Stay | 2 | 2017 | 6418 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2014 | 1438 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2812 | 0.060 |
Why?
|
| Cause of Death | 1 | 2015 | 3683 | 0.060 |
Why?
|
| Health Surveys | 1 | 2014 | 4037 | 0.060 |
Why?
|
| Linear Models | 1 | 2014 | 5866 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 12447 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3680 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 26049 | 0.050 |
Why?
|
| Recurrence | 1 | 2015 | 8426 | 0.050 |
Why?
|
| Self Report | 1 | 2014 | 3723 | 0.050 |
Why?
|
| Prevalence | 1 | 2019 | 15689 | 0.050 |
Why?
|
| Age Factors | 2 | 2015 | 18381 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 10754 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 12043 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 7798 | 0.040 |
Why?
|
| Mental Health | 1 | 2014 | 3251 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 41457 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 20988 | 0.040 |
Why?
|
| Adolescent | 3 | 2017 | 88234 | 0.040 |
Why?
|
| Drug Monitoring | 2 | 2015 | 960 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 54360 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 6925 | 0.030 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2019 | 348 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 4910 | 0.030 |
Why?
|
| Receptor, erbB-2 | 2 | 2016 | 2553 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6305 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13635 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 935 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39063 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 1635 | 0.020 |
Why?
|
| Logistic Models | 2 | 2016 | 13245 | 0.020 |
Why?
|
| Probability | 1 | 2016 | 2475 | 0.020 |
Why?
|
| Health Resources | 1 | 2016 | 933 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2015 | 883 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 59179 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2015 | 1375 | 0.020 |
Why?
|
| Body Weight | 1 | 2015 | 4614 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 3194 | 0.010 |
Why?
|
| Medicare | 1 | 2020 | 6765 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2015 | 8472 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13495 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 20074 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 7871 | 0.010 |
Why?
|
Concepts
(152)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_